GeneDx Holdings (WGS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tycho Peterson from Jefferies upgraded the rating on the stock to a Buy and gave it a $80.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tycho Peterson has given his Buy rating due to a combination of factors that highlight GeneDx Holdings’ potential for growth and profitability. The company’s projected 30% volume growth for 2025, particularly driven by the NICU and new indications, is a significant factor. This growth is expected to be supported by a reduction in the cost of goods sold, which will allow for margin expansion.
Another reason for the Buy rating is the compelling valuation of GeneDx Holdings, especially after a recent sell-off, making it an attractive investment compared to its peers. The company’s competitive advantage in the diagnostics field, with a substantial database of genotypic and phenotypic data, positions it well against limited competition. Additionally, the potential for further cost improvements through automation presents an opportunity for increased savings and profitability.
Peterson covers the Healthcare sector, focusing on stocks such as Exact Sciences, Qiagen, and Bruker. According to TipRanks, Peterson has an average return of 4.5% and a 52.06% success rate on recommended stocks.
In another report released on May 1, BTIG also maintained a Buy rating on the stock with a $100.00 price target.